Key result
ABCC3 promoter methylation shows no impact on clopidogrel response in ischemic stroke patients.
Why the study?
ABCC3 encodes MRP3, which mediates the transport of many drugs and is implicated in clopidogrel resistance.
Does ABCC3 promoter methylation affect clopidogrel response (maximum platelet aggregation) in Chinese ischemic stroke patients with CYP2C19*1/*1 genotype?
Cohort (n=87)
No
Does ABCC3 promoter methylation affect clopidogrel response (maximum platelet aggregation) in Chinese ischemic stroke patients with CYP2C19*1/*1 genotype?
ABCC3 promoter methylation inversely correlates with ABCC3 mRNA expression but does not significantly impact maximum platelet aggregation or clopidogrel response in Chinese ischemic stroke patients.
Answers are grounded in this paper and cite their sources.
Offers no current utility for ABCC3 methylation in clopidogrel therapy; leaves open epigenetic factors affecting platelet aggregation.
Multidrug resistance protein 3 (MRP3), encoded by ABCC3, is an ATP-dependent efflux pump mediating the transport of many drugs, implicated in clopidogrel resistance. This study enrolled 87 ischemic stroke patients with CYP2C19*1/*1 genotype, who received clopidogrel (75 mg/day) for at least 5 days before discharge. The maximum platelet aggregation (MPA) was measured by light transmittance aggregometry (LTA) to assess platelet function. Whole blood samples were obtained to evaluate the ABCC3 promoter methylation and mRNA expression of ABCC3. Pyrosequencing was carried out to investigate ABCC3 methylation and ABCC3 mRNA expression was evaluated by qPCR. The ABCC3 methylation was neither significantly different among the four MPA quartile groups (P = 0.275) nor independently associated with MPA values (R = 0.100, P = 0.358). However, the ABCC3 promoter methylation status in 87 clinical samples from patients correlated inversely with the expression of ABCC3 (R = - 0.854, P < 0.001). In addition, the ABCC3 expression was neither significantly different among the four quartile groups (P = 0.499) nor independently associated with MPA values (R = 0.060, P = 0.582). ABCC3 promoter methylation does not seem to exhibit any impact on MPA and clopidogrel response at all.
No takes yet. Share an insight, caveat, or question.
Jie et al. (2014) conducted a cohort in Ischemic stroke (n=87). Clopidogrel was evaluated on Association of ABCC3 promoter methylation with maximum platelet aggregation (MPA) (R 0.100, p=0.358). In Chinese ischemic stroke patients, ABCC3 promoter methylation was inversely correlated with ABCC3 mRNA expression (R = -0.854) but had no significant impact on clopidogrel response (P = 0.358).
Synapse has enriched 10 related papers. Consider them for comparative context: